Factor VIII Coagulant Activity (FVIII:C) as an Independent Predictor of Bleeding across Different Subtypes of Von Willebrand Disease (VWD)
ASH 2024 ABSTRACT #3982
© 2025 STAR Therapeutics Inc.
Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD)
SOUTH SAN FRANCISCO, CA, June 26, 2024 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies...
Star Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer
SOUTH SAN FRANCISCO, CA, January 3, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...
Star Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, CA, January 2, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...
Star Therapeutics Appoints Matthew Fust as Independent Director and Audit Chair
SOUTH SAN FRANCISCO, CA, December 5, 2023 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...
Star Therapeutics raises $90 million financing to accelerate its pipeline of novel antibody therapies and growth of its portfolio companies
SOUTH SAN FRANCISCO, CA, September 5, 2023 – Star’s innovation engine has driven rapid advancement of internally discovered first‑in‑class antibody therapeutics...
Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease
SOUTH SAN FRANCISCO, CA, May 23, 2023 – Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies...
Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First-in-Class Antibody Therapy for von Willebrand Disease
Phase 1 Clinical Trial Advances with First Subject Dosed in the E.U. and IND Accepted in the U.S...
Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapies
Drug discovery approach uncovers novel biology for treatments that can [...]
